Loading
Build a shared, not-for-profit clinical unit that runs early combination trials to a standard recipe, so that small companies and academics can test pairs without building their own trial machinery.
Early combination trials repeat the same work: pharmacokinetic interaction, overlapping toxicity, dose finding. A utility unit with standard protocols, pre-negotiated site contracts and a fixed price per arm (analogous to a contract research organisation but mission-driven and data-open) would lower the barrier for combinations that no single company will sponsor, especially those pairing drugs from different owners.
Shares The Institute of Cancer Research, The Royal Marsden, Cancer Research UK.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares The Institute of Cancer Research, Cancer Research UK.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.